Literature DB >> 9103511

Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.

X Y Chu1, Y Kato, K Niinuma, K I Sudo, H Hakusui, Y Sugiyama.   

Abstract

Irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11), is a potent anticancer drug that is increasingly used in chemotherapy. A frequent limiting side effect involves gastrointestinal toxicity (diarrhea), which is thought to be related to the biliary excretion of CPT-11 and its metabolites. Accordingly, the biliary excretion mechanisms for both the lactone and carboxylate forms of CPT-11 and its metabolites, SN-38 and its glucuronide (SN38-Glu), were investigated using Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rats (EHBR), with the latter being mutant rats with a genetic deficiency of the canalicular multispecific organic anion transporter. After i.v. administration of CPT-11, the biliary excretion clearance, defined as the biliary excretion rate normalized to the hepatic concentration, of both the lactone and carboxylate forms of SN38-Glu was much lower in EHBR. The biliary excretion clearance for the carboxylate form of both CPT-11 and SN-38 was also substantially smaller in EHBR and showed marked saturation with increasing dose only in SD rats. On the other hand, the biliary excretion clearance for the lactone forms of CPT-11 and SN-38 showed only a minimal difference in EHBR, compared with SD rats. These results suggest that, for the carboxylate form of CPT-11 and SN-38 and the carboxylate and lactone forms of SN38-Glu, there exists a specific transport system at the bile canalicular membrane that is deficient in EHBR. To confirm this hypothesis, the uptake of these substrates by isolated hepatic canalicular membrane vesicles (CMV) was examined. ATP-dependence was clearly observed for the uptake of these four compounds by CMV prepared from SD rats but not by CMV from EHBR. In addition, the compounds inhibited the ATP-dependent uptake of S-(2,4-dinitrophenyl) glutathione by CMV from SD rats, in a concentration-dependent manner. These results suggest that the biliary excretion of the carboxylate forms of CPT-11 and SN-38 and the carboxylate and lactone forms of SN38-Glu is mediated by the multispecific organic anion transporter, which is deficient in EHBR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103511

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  Exploring the structure-activity relationships of ABCC2 modulators using a screening approach.

Authors:  Gloria Wissel; Pavel Kudryavtsev; Leo Ghemtio; Päivi Tammela; Peter Wipf; Marjo Yliperttula; Moshe Finel; Arto Urtti; Heidi Kidron; Henri Xhaard
Journal:  Bioorg Med Chem       Date:  2015-04-17       Impact factor: 3.641

2.  Mechanism of Resistance to Camptothecin, a Cytotoxic Plant Secondary Metabolite, by Lymantria sp. Larvae.

Authors:  T P Sajitha; B L Manjunatha; R Siva; Navdeep Gogna; Kavita Dorai; G Ravikanth; R Uma Shaanker
Journal:  J Chem Ecol       Date:  2018-05-25       Impact factor: 2.626

3.  Transfected rat cMOAT is functionally expressed on the apical membrane in Madin-Darby canine kidney (MDCK) cells.

Authors:  S Kinoshita; H Suzuki; K Ito; K Kume; T Shimizu; Y Sugiyama
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

4.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 5.  Interplay of drug metabolizing enzymes with cellular transporters.

Authors:  Michaela Böhmdorfer; Alexandra Maier-Salamon; Juliane Riha; Stefan Brenner; Martina Höferl; Walter Jäger
Journal:  Wien Med Wochenschr       Date:  2014-09-10

6.  Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Authors:  K Arimori; N Kuroki; A Kumamoto; N Tanoue; M Nakano; E Kumazawa; A Tohgo; M Kikuchi
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

7.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

Review 8.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

Review 9.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

10.  Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.

Authors:  Qingyu Zhou; Alex Sparreboom; Eng-Huat Tan; Yin-Bun Cheung; Ann Lee; Donald Poon; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.